Shih-Fan Lai1,2, Yu-Hsuan Chen2, Wen-Hung Kuo3, Huang-Chun Lien4, Ming-Yang Wang3, Yen-Shen Lu2,5, Chiao Lo3, Sung-Hsin Kuo6,7,8, Ann-Lii Cheng2,5,9, Chiun-Sheng Huang10. 1. Division of Radiation Oncology, Department of Medical Imaging, National Taiwan University Hospital, Hsin-Chu Branch, Hsin-Chu City, Taiwan. 2. Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, No. 7, Chung-Shan South Road, Taipei, 100, Taiwan. 3. Department of Surgery, National Taiwan University Hospital and National Taiwan University Cancer Center, No. 7, Chung-Shan South Road, Taipei, Taiwan. 4. Department of Pathology, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan. 5. Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan. 6. Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital and National Taiwan University Cancer Center, No. 7, Chung-Shan South Road, Taipei, 100, Taiwan. shkuo101@ntu.edu.tw. 7. Cancer Research Center, National Taiwan University College of Medicine, Taipei, Taiwan. shkuo101@ntu.edu.tw. 8. Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. shkuo101@ntu.edu.tw. 9. Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan. 10. Department of Surgery, National Taiwan University Hospital and National Taiwan University Cancer Center, No. 7, Chung-Shan South Road, Taipei, Taiwan. huangcs@ntu.edu.tw.
Abstract
BACKGROUND: Administering postmastectomy radiotherapy (PMRT) to patients with T1-2 breast cancer and one to three positive axillary lymph nodes (ALNs) is controversial. The current study assessed the association of clinicopathologic features and molecular subclassification with locoregional recurrence (LRR) in patients who did not receive PMRT. METHODS: Between January 2004 and December 2008, 293 patients with T1-2 breast cancer and one to three positive ALNs not receiving PMRT were analyzed. Most of the patients received an anthracycline- or taxane-based regimen or both. The patients were divided according to the four molecular subtypes as follows: luminal A/B, luminal human epidermal growth factor receptor 2 (HER2), HER2, and triple-negative breast cancer. Overall survival (OS) and LRR were calculated using the Kaplan-Meier method, and the clinicopathologic prognostic factors were compared using log-rank tests and the Cox regression model. RESULTS: After a median follow-up period of 82.8 months, the 10-year LRR and OS were respectively 10 %, and 88.9 %. The patients with triple-negative breast cancer had a higher 5-year LRR rate (10.6 %) than those without this disease (4.2 %) (p = 0.05). Multivariate analysis showed that young age (≤40 years), tumor larger than 3 cm, and the presence of extensive intraductal components were significant risk factors for LRR. The 5-year LRR was 3.1 % for the patients without the aforementioned risk factors, 7.9 % for those with one risk factor, and 25 % for those with two or more risk factors (p < 0.001). CONCLUSIONS: Administering modern systemic therapy to early breast cancer patients not receiving PMRT reduced the LRR rate. Younger patients, those with a tumor larger than 3 cm, and those with extensive intraductal components might benefit from PMRT.
BACKGROUND: Administering postmastectomy radiotherapy (PMRT) to patients with T1-2breast cancer and one to three positive axillary lymph nodes (ALNs) is controversial. The current study assessed the association of clinicopathologic features and molecular subclassification with locoregional recurrence (LRR) in patients who did not receive PMRT. METHODS: Between January 2004 and December 2008, 293 patients with T1-2breast cancer and one to three positive ALNs not receiving PMRT were analyzed. Most of the patients received an anthracycline- or taxane-based regimen or both. The patients were divided according to the four molecular subtypes as follows: luminal A/B, luminal humanepidermal growth factor receptor 2 (HER2), HER2, and triple-negative breast cancer. Overall survival (OS) and LRR were calculated using the Kaplan-Meier method, and the clinicopathologic prognostic factors were compared using log-rank tests and the Cox regression model. RESULTS: After a median follow-up period of 82.8 months, the 10-year LRR and OS were respectively 10 %, and 88.9 %. The patients with triple-negative breast cancer had a higher 5-year LRR rate (10.6 %) than those without this disease (4.2 %) (p = 0.05). Multivariate analysis showed that young age (≤40 years), tumor larger than 3 cm, and the presence of extensive intraductal components were significant risk factors for LRR. The 5-year LRR was 3.1 % for the patients without the aforementioned risk factors, 7.9 % for those with one risk factor, and 25 % for those with two or more risk factors (p < 0.001). CONCLUSIONS: Administering modern systemic therapy to early breast cancerpatients not receiving PMRT reduced the LRR rate. Younger patients, those with a tumor larger than 3 cm, and those with extensive intraductal components might benefit from PMRT.
Authors: Maria Cristina Leonardi; Ida Rosalia Scognamiglio; Barbara Alicja Jereczek-Fossa; Giovanni Corso; Patrick Maisonneuve; Samantha Dicuonzo; Damaris Patricia Rojas; Maria Alessia Zerella; Anna Morra; Marianna Alessandra Gerardi; Mattia Zaffaroni; Alessandra De Scalzi; Antonia Girardi; Francesca Magnoni; Emilia Montagna; Cristiana Iuliana Fodor; Viviana Enrica Galimberti; Paolo Veronesi; Roberto Orecchia; Roberto Pacelli Journal: Breast Cancer Res Treat Date: 2021-04-27 Impact factor: 4.872
Authors: Hae Jin Park; Kyung Hwan Shin; Jin Ho Kim; Seung Do Ahn; Ja Young Kim; Won Park; Yong Bae Kim; Yeon-Joo Kim; Jin Hee Kim; Kyubo Kim; Kyung Ran Park; Hyun Soo Shin; Bae Kwon Jeong; Sun Young Lee; Suzy Kim Journal: Cancer Res Treat Date: 2016-10-19 Impact factor: 4.679
Authors: Ji Hyeon Joo; Su Ssan Kim; Byung Ho Son; Seung Do Ahn; Jin Hong Jung; Eun Kyung Choi; Sei Hyun Ahn; Jong Won Lee; Hee Jeong Kim; Beom Seok Ko Journal: Cancer Res Treat Date: 2018-10-16 Impact factor: 4.679